Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.70 |
| ▸ | EGFR | P00533 | 14/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | ABL1 | P00519 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | RAF1 | P04049 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.66 |
| ▸ | ABL2 | P42684 | 2/20 | 0.66 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | GMNN | O75496 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13646432 | 0.88 | EGFR (0.75) | FBP1EGFRKDM4EMAPTMAPK1 | |
| Erlotinib SCHEMBL13087124 | 0.86 | EGFR (0.78) | FBP1EGFRMAPTABL1LMNA | |
| SCHEMBL13646435 | 0.86 | FBP1 (0.71) | FBP1EGFRKDRERBB2AURKA | |
| SCHEMBL13646434 | 0.85 | EGFR (0.68) | FBP1EGFRABL1LMNARAF1 | |
| SCHEMBL5606140 | 0.82 | FBP1 (1.00) | FBP1EGFRKDM4EMAPTMAPK1 | |
| SCHEMBL8258194 | 0.81 | EGFR (0.83) | FBP1EGFRKDM4EMAPTMAPK1 | |
| SCHEMBL13646428 | 0.81 | EGFR (0.70) | FBP1EGFRABL1LMNARAF1 | |
| Tyrphostin Ag-1478 SCHEMBL93838 | 0.80 | EGFR (1.00) | FBP1EGFRKDM4EMAPTMAPK1 | |
| Tyrphostin Ag-1478 SCHEMBL31079458 | 0.80 | EGFR (1.00) | FBP1EGFRKDM4EMAPTMAPK1 | |
| Tyrphostin Ag-1478 SCHEMBL29483198 | 0.80 | EGFR (1.00) | FBP1EGFRKDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | FBP1 3745/4885EGFR 19/4885KDM4E 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.